financetom
Business
financetom
/
Business
/
Kerrisdale Capital Is Short Lumen Technologies: Here's What To Know
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kerrisdale Capital Is Short Lumen Technologies: Here's What To Know
Aug 29, 2024 4:12 AM

Lumen Technologies, Inc. ( LUMN ) shares are trading lower Tuesday after Kerrisdale Capital announced a short position and released a bearish report on the stock. 

The Details:

In its report titled "AI-N't Gonna Fix This Mess," Kerrisdale Capital expressed doubt regarding an AI-fueled turnaround for Lumen.  

"Lumen has used a string of buzzy headlines to portray the rise of AI as key to resurrecting the company's dimming turnaround hopes but it's really just a transparent attempt to glom onto the hottest theme in the market," the short seller said. 

Benzinga reached out to Lumen Technologies ( LUMN ) for comment, but the company did not immediately respond. 

Read Next: Apple Announces CFO Transition, iPhone 16 Debut: What To Know

Kerrisdale Capital claimed Lumen's recently announced contracts are an attempt to raise capital amid declining recurring revenue and liquidity concerns. The short seller pointed to a decrease of 8.6% in Lumen’s Core Business segment revenue in the most recent quarter, the worst in company history. 

Lumen Technologies ( LUMN ) shares are falling Tuesday as investors digest the short report. According to data from Benzinga Pro, Lumen's stock is up more than 200% over the past month and is trading well-above its 50-day moving average of $2.75. 

Will LUMN Stock Go Up?

When trying to assess whether or not Lumen Technologies ( LUMN ) will trade higher from current levels, it's a good idea to take a look at analyst forecasts.

Wall Street analysts have an average 12-month price target of $3.64 on Lumen Technologies ( LUMN ). The Street high target is currently at $7 and the Street low target is $1. Of all the analysts covering Lumen Technologies ( LUMN ), no one has positive ratings, 4 have neutral ratings and 4 have negative ratings.

In the last month, 8 analysts have adjusted price targets. Here's a look at recent price target changes [Analyst Ratings]. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Lumen Technologies ( LUMN ) have performed in recent history.

Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Lumen Technologies ( LUMN ) is 192.6% up year-to-date. The average analyst price target suggests the stock could have further downside ahead.

For a broad overview of everything you need to know about Lumen Technologies ( LUMN ), visit here. If you want to go above and beyond, there's no better tool to help you do just that than Benzinga Pro. Start your free trial today.

LUMN Price Action: According to Benzinga Pro, Lumen Technologies ( LUMN ) shares are down 10.5% at $5.48 at the time of publication Tuesday.

Read Also:

What’s Going On With EV-Maker Rivian’s Stock?

This image was generated using artificial intelligence via Dall-E 3.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ANI Pharmaceuticals Launches Estradiol Gel Following US FDA's Final Approval for Abbreviated New Drug Application
ANI Pharmaceuticals Launches Estradiol Gel Following US FDA's Final Approval for Abbreviated New Drug Application
Oct 25, 2024
08:00 AM EDT, 10/25/2024 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) said Friday it has launched Estradiol Gel, a generic version of the EstroGel, after receiving the US Food and Drug Administration's final approval for its Abbreviated New Drug Application. The prescription medicine is meant to alleviate certain symptoms of menopause. Price: 61.69, Change: +2.41, Percent Change: +4.07 ...
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Oct 25, 2024
On Friday, Sanofi SA ( SNY ) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company reported third-quarter sales of 13.44 billion euros or $14.79 billion, beating the consensus of $13.97 billion. Sales increased 12.3% year over year and 15.7% on constant currency, led by solid growth from...
Colgate-Palmolive lifts lower end of 2024 results forecast on steady demand
Colgate-Palmolive lifts lower end of 2024 results forecast on steady demand
Oct 25, 2024
Oct 25 (Reuters) - Toothpaste maker Colgate-Palmolive ( CL ) raised the lower end of its annual sales and profit forecasts on Friday, after beating third-quarter estimates on resilient demand for its high-priced products. WHY IS IT IMPORTANT? Consumers have been prioritizing spending on daily essentials over discretionary items amid rising cost of living, fueling sales for consumer packaged goods...
Agnico Eagle Mines to Invest $40 Million in ATEX Resources for Copper-Gold Project Exposure
Agnico Eagle Mines to Invest $40 Million in ATEX Resources for Copper-Gold Project Exposure
Oct 25, 2024
08:18 AM EDT, 10/25/2024 (MT Newswires) -- Agnico Eagle Mines ( AEM ) said Friday it has entered an agreement to invest $40 million in ATEX Resources through a non-brokered private placement. The deal involves subscribing for around 33.9 million ATEX Resources units at 1.63 Canadian dollars ($1.18) per unit, each consisting of one common share and half of a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved